Kenvue Inc. (NYSE:KVUE) Receives $25.33 Consensus Target Price from Brokerages

Shares of Kenvue Inc. (NYSE:KVUE - Get Free Report) have been assigned a consensus rating of "Hold" from the twelve analysts that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $25.33.

KVUE has been the subject of a number of recent research reports. Citigroup raised their price target on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Redburn Atlantic began coverage on shares of Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Finally, Barclays lifted their target price on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a report on Monday, May 12th.

Kenvue Price Performance

KVUE stock traded down $0.00 during midday trading on Friday, hitting $23.55. The company's stock had a trading volume of 19,711,476 shares, compared to its average volume of 16,356,601. The company has a 50 day moving average of $23.26 and a two-hundred day moving average of $22.64. Kenvue has a 12 month low of $17.67 and a 12 month high of $25.17. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $45.18 billion, a price-to-earnings ratio of 44.43, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period last year, the company earned $0.28 earnings per share. Kenvue's revenue was down 3.9% on a year-over-year basis. On average, analysts expect that Kenvue will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KVUE. Norges Bank acquired a new position in Kenvue during the fourth quarter worth about $521,348,000. Starboard Value LP bought a new stake in shares of Kenvue during the fourth quarter worth about $467,864,000. Franklin Resources Inc. grew its holdings in shares of Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after purchasing an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Kenvue by 4.9% during the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company's stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.